Back to Results

Procept Biorobotics Corp (PRCT)

PROCEPT BioRobotics Corp. is a healthcare equipment company focused on surgical robotics for urology. The company develops, manufactures, and commercializes systems used in minimally invasive urologic procedures in the United States and international markets. Its product portfolio includes the AquaBeam Robotic System, an image-guided platform designed for robotic surgery in the treatment of benign prostatic hyperplasia, as well as the HYDROS Robotic System, which is used to deliver Aquablation therapy for men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Incorporated in 2007, PROCEPT BioRobotics is headquartered in San Jose, California, and its common stock trades on the NASDAQ exchange under the symbol PRCT.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-PRCT
$27.69
43.5% Upside
Undervalued
$21.64
12.1% Upside
Fair
Good
0.0%
October 29, 2026
3.3x
3.3x
1.105 B
955 M
6.5%
97.4%
3.5
77.4%
Valuation • Fair Value

Procept Biorobotics Corp (NASDAQ-PRCT) Fair Value by Valuation Model

Review the available estimates for Procept Biorobotics Corp (NASDAQ-PRCT), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$27.69

Estimated upside of 43.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$30.99

Discounted cash flow valuation reference.

EPV Fair Value

$16.85

Earnings power value estimate.

Comps Fair Value

$26.20

Comparable-company valuation reference.

Analyst Price Target

$21.64

Analysts imply upside of 12.1%.

How to read these valuation models

Use the 6 available valuation references for Procept Biorobotics Corp (NASDAQ-PRCT) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Procept Biorobotics Corp (NASDAQ-PRCT)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

337.3 M

Current operating scale indicator.

Revenue Forecast

395.5 M

Forward revenue estimate.

EBITDA

-110.1 M

Current operating profitability reference.

EBITDA Forecast

-33.862 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Procept Biorobotics Corp (NASDAQ-PRCT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Procept Biorobotics Corp (NASDAQ-PRCT)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-2.46

No elevated caution signal from this screen.

Altman Z-Score

3.5

Relatively strong balance-sheet zone.

FCF / Net Income

77.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Procept Biorobotics Corp (NASDAQ-PRCT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Procept Biorobotics Corp (NASDAQ-PRCT)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 29, 2026

Days to Earnings

41

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Procept Biorobotics Corp (NASDAQ-PRCT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Procept Biorobotics Corp (NASDAQ-PRCT) Stock Forecast & Technical Outlook

Review Procept Biorobotics Corp (NASDAQ-PRCT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Procept Biorobotics Corp (NASDAQ-PRCT) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Procept Biorobotics Corp (NASDAQ-PRCT) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Procept Biorobotics Corp (NASDAQ-PRCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Procept Biorobotics Corp (NASDAQ-PRCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Procept Biorobotics Corp (NASDAQ-PRCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Procept Biorobotics Corp (NASDAQ-PRCT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Procept Biorobotics Corp (NASDAQ-PRCT) has a Hold consensus, with 3 buy, 9 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 9
Sell 0
FAQ • Fast Investor Answers

Procept Biorobotics Corp (NASDAQ-PRCT) Stock FAQ

Data-supported answers about Procept Biorobotics Corp (NASDAQ-PRCT), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$27.69
Estimated upside 43.5%
Valuation Rating
Undervalued
Estimated upside of 43.5%
Analyst Target
$21.64
Implied upside 12.1%
Financial Health
Good
Current financial-health read

The current fair value estimate for Procept Biorobotics Corp (NASDAQ-PRCT) is $27.69. This implies an estimated upside of 43.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 43.5% versus the current market price.

The available analyst price target for Procept Biorobotics Corp (NASDAQ-PRCT) is $21.64. The analyst target implies estimated upside of 12.1%.

The current financial health read for Procept Biorobotics Corp (NASDAQ-PRCT) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Procept Biorobotics Corp (NASDAQ-PRCT) is October 29, 2026.

The latest available data indicates no current dividend yield for Procept Biorobotics Corp (NASDAQ-PRCT).

The current market capitalization listed for Procept Biorobotics Corp is 1.105 B.

The current enterprise value listed for Procept Biorobotics Corp is 955 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Procept Biorobotics Corp is NASDAQ-PRCT, and the stock is listed on NASDAQ.

Procept Biorobotics Corp (NASDAQ-PRCT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Procept Biorobotics Corp is 6.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Procept Biorobotics Corp is 97.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 177.6 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 139 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 117.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 62.81 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 50.873 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.286 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 41.807 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 40.289 B
DXCM NASDAQ DexCom Inc Fair Value Fair Market Cap 33.717 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 32.188 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.559 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 28.967 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.25 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 19.991 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 18.189 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.123 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.51 B
BAX NYSE Baxter International Inc Fair Value Undervalued Market Cap 11.788 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.577 B